Latest News

  • INVESTMENT

    6 Apr 2026

    RNA Gets a $2.4B Promotion at Eli Lilly

  • PARTNERSHIPS

    31 Mar 2026

    RNA Meets Cell Therapy, and Texas Is Holding the Handshake

  • REGULATORY

    26 Mar 2026

    No Trial? No Problem. FDA Rewrites the RNA Rules

  • INVESTMENT

    23 Mar 2026

    New Funding Backs Precision in mRNA Medicine

Fatty Bubbles and the $2.25 Billion Peace

Red Moderna logo signage mounted on building exterior above entrance

PARTNERSHIPS

17 Mar 2026

Moderna settles landmark LNP patent dispute for up to $2.25B, securing a royalty-free delivery license for its infectious disease vaccine programs

Aktis Oncology logo displayed over a laboratory research setting

INVESTMENT

12 Jan 2026

A New Pulse in Biotech IPOs Starts With Oncology

Aktis Oncology’s planned Nasdaq debut, backed by Eli Lilly, suggests investors are cautiously returning to targeted cancer innovation

Concept image illustrating generative AI applied to mRNA drug design

TECHNOLOGY

7 Jan 2026

Can Generative AI Crack the Code of mRNA Design?

New preclinical data suggest generative AI could streamline mRNA design and reduce costly trial-and-error for future therapies

Icahn School of Medicine at Mount Sinai where researchers develop selective mRNA drug designs

RESEARCH

19 Dec 2025

A New Twist Makes mRNA Drugs More Selective

Preclinical US research in mouse models suggest redesigned mRNA activates mainly in diseased cells, hinting at safer drugs as human trials...

HHS press release signaling reduced BARDA support for mRNA development

REGULATORY

18 Dec 2025

BARDA Pullback Signals New Phase for US mRNA Development

HHS is winding down BARDA-backed mRNA vaccine programs, prompting analysts to see a shift toward commercially focused mRNA strategies

Aerial view of the University of Texas campus where new AI mRNA research was developed.

INNOVATION

17 Dec 2025

mRNA Design Enters a More Predictive Era

New AI research forecasts mRNA protein output earlier, helping developers refine drug designs before costly lab testing begins

Crowd gathered outside Moderna headquarters building in daylight

INVESTMENT

15 Dec 2025

Moderna Bets on Debt to Power mRNA’s Next Act

Moderna secures a $1.5B non-dilutive term loan to fund mRNA growth beyond COVID, highlighting why established players may prioritize long-...

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.